Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

TG103

Stage Phase 3Stale

Sponsor CSPC Baike (Shandong) Biopharmaceutical Co

Route injection

Class GLP-1 RA

Mechanism This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase 3 study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of TG103 injection, a GLP-1 receptor agonist, for weight man

Sources

registry, as of 2025-08-11Stale

https://clinicaltrials.gov/study/NCT05997576

A Study of TG103 Injection in Non-diabetic Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Enrollment 675. Conditions Overweight or Obesity. This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase 3 study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of TG103 injection, a GLP-1 receptor agonist, for weight management in non-diabetic patients with BM

ClinicalTrials.gov NCT05997576 protocol and results modules

registry, as of 2025-05-14Stale

https://clinicaltrials.gov/study/NCT06226090

A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Enrollment 314. Conditions Obesity; Overweight. This study is a randomized, double-blind, placebo-controlled, parallel phase 2 study to evaluate efficacy, safety, pharmacokinetic characteristics and immunogenicity of TG103 injection for weight management in non-diabetic patients with overweight in the presence of comorbidities

ClinicalTrials.gov NCT06226090 protocol and results modules

registry, as of 2021-10-01Stale

https://clinicaltrials.gov/study/NCT05063253

A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes. Overall status UNKNOWN. Phases PHASE2. Lead sponsor CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Enrollment 208. Conditions Type 2 Diabetes Mellitus. The main purpose of this study is to evaluate the efficacy, safety, PK and PD characteristics of different doses of TG103 injection in overweight/obese subjects with type 2 diabetes mellitus.

ClinicalTrials.gov NCT05063253 protocol and results modules

registry, as of 2022-05-23Stale

https://clinicaltrials.gov/study/NCT05299697

A Study of TG103 Injection in Overweight or Obesity. Overall status UNKNOWN. Phases PHASE2. Lead sponsor CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Enrollment 195. Conditions Overweight or Obesity. This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase II study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of two dose levels of TG103 injection, a GLP-1 receptor agonist, in the management of overweight or

ClinicalTrials.gov NCT05299697 protocol and results modules

registry, as of 2023-06-22Stale

https://clinicaltrials.gov/study/NCT04855292

A Study of TG103 Injection in Overweight/Obese Subjects Without Diabetes. Overall status COMPLETED. Phases PHASE1. Lead sponsor CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Enrollment 48. Conditions Diabetes. The main purpose of this study is to assess the safety and tolerability of multiple doses of TG103 injection in overweight/obese subjects without diabetes

ClinicalTrials.gov NCT04855292 protocol and results modules

Studies

A Study of TG103 Injection in Non-diabetic Overweight or Obesity

Registry NCT05997576

Phase Phase 3

Status Completed

Enrollment 675

Start 2023-11-22

Primary completion 2025-02-17

Study completion 2025-03-03

Catalyst Primary completion. 2025-02-17. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

TG103 22.5 mg

Dose 22.5 mg

Comparator placebo

Population Overweight or Obesity

Placebo

Population Overweight or Obesity

A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity

Registry NCT06226090

Phase Phase 2

Status Completed

Enrollment 314

Start 2024-02-21

Primary completion 2024-09-26

Study completion 2024-10-24

TG103 7.5 mg

Dose 7.5 mg

Regimen once weekly

Weeks 24

Comparator placebo

Population Obesity; Overweight

Placebo 7.5 mg

Dose 7.5 mg

Regimen once weekly

Weeks 24

Population Obesity; Overweight

TG103 15 mg

Dose 15 mg

Regimen once weekly

Weeks 24

Comparator placebo

Population Obesity; Overweight

Placebo 15 mg

Dose 15 mg

Regimen once weekly

Weeks 24

Population Obesity; Overweight

TG103 22.5 mg

Dose 22.5 mg

Regimen once weekly

Weeks 24

Comparator placebo

Population Obesity; Overweight

Placebo 22.5 mg

Dose 22.5 mg

Regimen once weekly

Weeks 24

Population Obesity; Overweight

A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes

Registry NCT05063253

Phase Phase 2

Enrollment 208

TG103, 15 mg

Dose 15 mg

Regimen once weekly

Comparator placebo

Population Type 2 Diabetes Mellitus

TG103, 22.5 mg

Dose 22.5 mg

Regimen once weekly

Comparator placebo

Population Type 2 Diabetes Mellitus

TG103, 30 mg

Dose 30 mg

Regimen once weekly

Comparator placebo

Population Type 2 Diabetes Mellitus

Placebo

Regimen once weekly

Population Type 2 Diabetes Mellitus

A Study of TG103 Injection in Overweight or Obesity

Registry NCT05299697

Phase Phase 2

Enrollment 195

Start 2022-05-20

Primary completion 2023-06-30

Study completion 2023-09-30

TG103 15 mg

Dose 15 mg

Comparator placebo

Population Overweight or Obesity

TG103 22.5 mg

Dose 22.5 mg

Comparator placebo

Population Overweight or Obesity

Placebo

Population Overweight or Obesity

A Study of TG103 Injection in Overweight/Obese Subjects Without Diabetes

Registry NCT04855292

Phase Phase 1

Status Completed

Enrollment 48

Start 2021-07-01

Primary completion 2022-12-01

Study completion 2023-01-01

TG103 injection 15 mg

Dose 15 mg

Regimen once weekly

Population Diabetes

TG103 injection 22.5 mg

Dose 22.5 mg

Regimen once weekly

Population Diabetes

TG103 injection 30 mg

Dose 30 mg

Regimen once weekly

Population Diabetes